Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions

Williamson, C, et al. Society for Investigate Dermatology (SID), May 2025

‍

This poster describes the preclinical development of a novel, fully human anti-OX40L monoclonal antibody (ABCL575) for the treatment of moderate-to-severe atopic dermatitis (AD). ABCL575 incorporates a modified Fc domain for half-life extension, with preclinical studies suggesting potential for improved dosing frequency and safety compared to clinical benchmarks.

Together, the data presented show:

• Potent functional activity that is equivalent to the most advanced clinical benchmark, with inhibition of OX40L signalling and T-cell activation in vitro and significant reduction of Th2 cytokines in vivo.
• Modified Fc domain that supports Fc-silencing and half-life extension, with a predicted human half-life of more than 60 days from preclinical in vivo PK data. 
• Positive nonclinical safety profile and favorable stability when formulated at high concentration.

‍